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Background: The new oral anticoagulants have demonstrated efficacy and safety in preventing stroke in patients with atrial fibrillation; however, 
one feature they all share is the lack of a specific antidote in cases of emergency. A humanized antibody fragment (Fab) against dabigatran is 
currently in development.
methods: Binding affinity and on- and off-rates for Fab:dabigatran interactions were tested (mean ± SD, n=3). Inhibition of glucuronidated 
dabigatran was tested using diluted thrombin time assay. Any thrombotic activity of the Fab was tested as fibrinopeptide A (FPA) generation in the 
absence or presence of an existing clot. Pharmacokinetics (PK) was determined by measuring functional and sum dabigatran and total Fab in the 
rat (n=3). Dabigatran etexilate (DE), 30 mg/kg, or warfarin, 3 mg/kg, was given to rats every 8 hrs to induce bleeding in a rat tail bleeding model. 
Increasing Fab doses were given to test for bleeding time (BT) reversal (n=4-6).
results: Binding affinity of Fab to dabigatran was 2 pM, with a rapid kon (7.3 ±6.4 x105/Ms) and slow koff (1.5 ±1.4 x10-6/s). The IC50 of 
dabigatran inhibition by Fab was 3.5 nM and IC50 of dabigatran metabolite inhibition was 2nM in human plasma. Addition of up to 3 mg/mL Fab 
did not increase FPA generation in presence of a preformed clot or in plasma. PK of the Fab in rats had a short initial t1/2 of 0.24 h and longer 
terminal t1/2 of 5.8 h. Clearance was low (1.95 mL/min/kg) and steady-state volume of distribution small (0.0688 L/kg). PK of the Fab was not 
affected by dabigatran. DE (30 mg/kg p.o.) given in 8 hr intervals achieved steady state levels of 1500 nM (~750 ng/mL), and resulted in ~2-
fold increase of tail cut BT. There was a rapid, dose-dependent decrease in BT after i.v. injection of Fab. Anticoagulation (clotting ex vivo) was also 
reversed. Treating rats with warfarin (0.5 mg/kg p.o.) over 3 days resulted in a 2-fold elevation of BT. Addition of similar doses of Fab had no effect 
on reversing this elevated BT.
conclusion: The Fab is specific and selective for dabigatran and reversed DE-induced blood loss in rats, correlating with reversal of ex vivo clotting 
tests. This agent holds promise for reversing dabigatran-induced anticoagulation and bleeding effects.
